An early move by the president has raised questions about what direction his second-term policy on drug costs will take.

President Donald Trump’s Medicare agency is seeking to bring more transparency to the US government’s drug price negotiation program, indicating plans to move forward with the second round of the program initiated by the Biden administration.

A short statement from CMS said the agency will consider ways to make Medicare price negotiations, begun under Biden, more transparent.

The U.S. government said on Wednesday it will aim for "greater transparency" in Medicare drug price negotiations under President Donald Trump's administration following criticism from the pharmaceutical industry for the Biden-era law.